Lawyer Bio : Julie Broadus Meigs, Ph.D.

Julie Broadus Meigs, Ph.D.

Tysons Corner

Dr. Meigs’ practice focuses on biotechnology patent prosecution, opinion work, and client counseling.  Her work includes the design and implementation of global intellectual property strategies, including life cycle management for pharmaceuticals and agricultural biotechnology.   
 
Dr. Meigs has technical experience in the areas of neuroscience, receptor biology, stem cell biology and cellular therapies, animal cloning, drug discovery and development, antibody technology and therapies, therapies for cancer and autoimmune disease, viral therapies, tissue regeneration and reinnervation, genetics and genomics-related technologies, mutagenesis and molecular cloning, interfering RNA and microRNAs, biological imaging, and agricultural biotechnology.
 
Dr. Meigs earned a doctorate degree in Neuroscience from the University of Illinois.  Her thesis work addressed genetic and molecular elements of stem cell division, cell fate determination, and evolution during early central nervous system development in insects.  As a postdoctoral fellow for Howard Hughes Medical Institute, Dr. Meigs’ research addressed the interplay of hormone signaling and orphan nuclear receptor networks during insect metamorphosis. 
 
Prior to entering the legal field, Dr. Meigs was a research scientist at Novartis Agricultural Biotechnology Research, Inc.

Additional Biography Info

Click on the headings below to view details

Close

Professional Activities

Registered to practice before the U.S. Patent and Trademark Office, 2001.
 
Admitted to the bar: 2005, Virginia; 2006, North Carolina.
 
American Intellectual Property Law Association, American Bar Association, North Carolina Bar Association (Citizen-Lawyer Committee Member), North Carolina Association of Women Attorneys.

Education

B.S., University of Illinois, magna cum laude.
 
Ph.D., University of Illinois.
 
J.D., George Mason University School of Law.

Prior Legal Experience

Senior Associate, Pillsbury Winthrop Shaw Pittman LLP, McLean, VA, 2008-2009; Associate, Pillsbury Winthrop Shaw Pittman LLP, McLean, VA, 2005-2008; Patent Agent, Pillsbury Winthrop Shaw Pittman LLP, McLean, VA, 2002-2005; Patent Agent, Jenkins Wilson Taylor & Hunt, Durham, NC, 2001-2002; Technical Specialist, Jenkins Wilson Taylor & Hunt, Durham, NC, 2000-2001.

Publications

Research Papers:
 
Broadus J., et al. (1999) The Drosophila bFTZ-F1 orphan nuclear receptor provides competence for stage-specific responses to the steroid hormone ecdysone. Molecular Cell 3:143-149.
 
Broadus J., et al. (1998) Staufen-dependent localization of prospero mRNA contributes to neuroblast daughter-cell fate. Nature 391:792-795.
 
Broadus J. & Doe C.Q. (1997) Extrinsic cues, intrinsic cues, and microfilaments regulate asymmetric protein localization in Drosophila neuroblasts. Current Biology 7:827-835.
 
Broadus J., et al. (1995) New neuroblast markers and the origin of the aCC/pCC neurons in the Drosophila central nervous system. Mechanisms of Development 54:1-10.
 
Broadus J. & Doe C.Q. (1995) Evolution of neuroblast identity: seven-up and prospero expression reveal homologous and divergent cell fates in Drosophila and Schistocerca. Development 121:3989-3996.
 
Hawrylak N., Ghosh P., Broadus J., Lauterbur P.C. & Greenough W.T. (1993) Nuclear magnetic resonance (NMR) imaging of iron oxide-labeled neural transplants. Experimental Neurology 121:181-192.
 
Reviews:
 
Fuerstenberg S., Broadus J. & Doe C.Q. (1998) Asymmetry and cell fate in the Drosophila embryonic CNS. International Journal of Developmental Biology 42(3):143-149.
 
Book Chapters:
 
Broadus J. & Spana E.P. (1999) "Asymmetric divisions and cell fate specification in the Drosophila central nervous system." In Cell Fate and Lineage Determination, S.A. Moody, Editor. 1999, Academic Press: San Diego. pp. 273-285.

Published Patent Applications:
 
Broadus J., et al. "Insect nuclear receptor genes and uses thereof," PCT International Publication No. WO 02/077157.
 
Broadus J., et al., "Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof," U.S. Patent Application Publication No. 20020160934.